A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT05354362 · TERMINATED
Trial details
- NCT number
- NCT05354362
- Sponsor
- Antengene Corporation
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-02
- Primary completion
- 2023-02-06
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.